Search Results - "Davidsohn, Matthew P."

Liquid biopsy epigenomic profiling for cancer subtyping by Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., Freedman, Matthew L.

“…Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the…”
Get full text

The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response by Berchuck, Jacob E, Adib, Elio, Abou Alaiwi, Sarah, Dash, Amit K, Shin, Jin Na, Lowder, Dallin, McColl, Collin, Castro, Patricia, Carelli, Ryan, Benedetti, Elisa, Deng, Jenny, Robertson, Matthew, Baca, Sylvan C, Bell, Connor, McClure, Heather M, El Zarif, Talal, Davidsohn, Matthew P, Lakshminarayanan, Gitanjali, Rizwan, Kinza, Skapura, Darlene G, Grimm, Sandra L, Davis, Christel M, Ehli, Erik A, Kelleher, Kaitlin M, Seo, Ji-Heui, Mitsiades, Nicholas, Coarfa, Cristian, Pomerantz, Mark M, Loda, Massimo, Ittmann, Michael, Freedman, Matthew L, Kaochar, Salma

“…African-American (AA) men are more likely to be diagnosed with and die from prostate cancer than European American (EA) men. Despite the central role of the…”
Get full text

Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling by El Zarif, Talal, Meador, Catherine B, Qiu, Xintao, Seo, Ji-Heui, Davidsohn, Matthew P, Savignano, Hunter, Lakshminarayanan, Gitanjali, McClure, Heather M, Canniff, John, Fortunato, Brad, Li, Rong, Banwait, Mandeep K, Semaan, Karl, Eid, Marc, Long, Henry, Hung, Yin P, Mahadevan, Navin R, Barbie, David A, Oser, Matthew G, Piotrowska, Zofia, Choueiri, Toni K, Baca, Sylvan C, Hata, Aaron N, Freedman, Matthew L, Berchuck, Jacob E

“…Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma…”
Get full text

Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping by Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., Freedman, Matthew L.

Get full text

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Nuzzo, Pier Vitale, Ravera, Francesco, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valença, Loana Bueno, El Zarif, Talal, Davidsohn, Matthew P., McClure, Heather, Oliveira, Thiago Martins, Vauchier, Charles, Pereira Mestre, Ricardo, Modesti, Mikol, Ravi, Praful, Patrikidou, Anna, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most…”
Get full text

Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling by Eid, Marc, Semaan, Karl, Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Lakshminarayanan, Gitanjali, El Zarif, Talal, Savignano, Hunter, Canniff, John, Saliby, Renee Maria, Saad, Eddy, Pomerantz, Mark, Baca, Sylvan, Freedman, Matthew, Berchuck, Jacob E, Choueiri, Toni K.

“…201 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive resistance phenotype that can develop in men with metastatic prostate adenocarcinoma…”
Get full text

Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study by Nizam, Amanda, Jindal, Tanya, Jiang, Cindy Y., Alhalabi, Omar, Davidsohn, Matthew P., Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Nguyen, Charles B, Oh, Eugene, Taylor, Amy K, Bilen, Mehmet Asim, Basu, Arnab, Kilari, Deepak, Emamekhoo, Hamid, Gupta, Shilpa, Grivas, Petros, Bellmunt, Joaquim, Campbell, Matthew T, Alva, Ajjai Shivaram, Koshkin, Vadim S

“…667 Background: SG is approved in pts with aUC refractory to platinum-based chemotherapy (PBT) and checkpoint inhibitor therapy (CPI). Data on SG outcomes in…”
Get full text

Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study by Nizam, Amanda, Jindal, Tanya, Jiang, Cindy Y., Alhalabi, Omar, Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Davidsohn, Matthew P., Nguyen, Charles B, Oh, Eugene, Taylor, Amy K, Lemke, Emily, Kilari, Deepak, Hoimes, Christopher J., Emamekhoo, Hamid, Gupta, Shilpa, Bellmunt, Joaquim, Grivas, Petros, Campbell, Matthew T, Alva, Ajjai Shivaram, Koshkin, Vadim S

“…537 Background: MAv is approved in pts with aUC without progression (PD) on 1L platinum-based therapy (PBT). As pts in the pivotal EV trials had not received…”
Get full text

Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation by Semaan, Karl, El Zarif, Talal, Seo, Ji-Heui, Eid, Marc, Canniff, John, Fortunato, Brad, Savignano, Hunter, Davidsohn, Matthew P., Lakshminarayanan, Gitanjali, Saad, Eddy, Saliby, Renee Maria, Bakouny, Ziad, Matar, Sayed, Nuzzo, Pier Vitale, Berchuck, Jacob E, Signoretti, Sabina, Braun, David A., Freedman, Matthew, Baca, Sylvan, Choueiri, Toni K.

“…449 Background: Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is associated with poor survival and heightened response to immune checkpoint…”
Get full text

Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma by El Zarif, Talal, Semaan, Karl, Eid, Marc, Seo, Ji-Heui, Garinet, Simon, Davidsohn, Matthew P., Sahgal, Pranshu, Fortunato, Brad, Canniff, John, Nassar, Amin H., Abou Alaiwi, Sarah, Bakouny, Ziad, Lakshminarayanan, Gitanjali, Savignano, Hunter, Lyons, Kevin, Matar, Sayed, Ali, Atef, Saad, Eddy, Saliby, Renee Maria, Cordeiro, Paulo, Zhang, Ziwei, El Ahmar, Nourhan, Laimon, Yasmin Nabil, Labaki, Chris, Shah, Valisha, Freeman, Dory, O’Toole, Jillian, Lee, Gwo-Shu Mary, Hwang, Justin, Pomerantz, Mark, Signoretti, Sabina, Van Allen, Eliezer M., Xie, Wanling, Berchuck, Jacob E., Viswanathan, Srinivas R., Braun, David A., Choueiri, Toni K., Freedman, Matthew L., Baca, Sylvan C.

“…Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs)…”
Get full text

Clinical outcomes of volume of disease on patients receiving enzalutamide abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Talal El Zarif, Matthew P. Davidsohn, Heather McClure, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Praful Ravi, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini

“…Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most…”
Get full text